-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓
Börse NasdaqUSDSymbol TVTX
Symbol TVTX
Währung
USD
Börse
Nasdaq Zeitzone: America/New_York
EBITDA 0
PEGRatio None
Buchwert None
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von
Dir gefallen die Informationen zu Travere Therapeutics, Inc.?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Travere Therapeutics, Inc.?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu Travere Therapeutics, Inc.?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Travere Therapeutics, Inc.?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
28 News & Informationen zur Travere Therapeutics, Inc. Aktie
Orbimed Advisors Llc Buys SPDR Biotech ETF, NeuroPace Inc, Janux Therapeutics Inc, Sells Haemonetics Corp, AbCellera Biologics Inc, Adverum Biotechnologies Inc
GuruFocus Article or News written by insider and the topic is about:
Armistice Capital, Llc Buys Iovance Biotherapeutics Inc, Burlington Stores Inc, Travere Therapeutics Inc, Sells TJX Inc, Lantheus Holdings Inc, Advance Auto Parts Inc
GuruFocus Article or News written by insider and the topic is about:
Albireo and Genpharm Announce Agreement to Commercialize Bylvay™ (odevixibat) in Saudi Arabia and the Gulf Region
– Bylvay is approved in the U.S. and EU as only once-daily drug indicated for patients with PFIC – – PFIC is a life-threatening liver disease and the…
Travere Posts Positive Topline Data in Phase 3 IgA Nephropathy Study, Shares Trade Higher
60 Biggest Movers From Yesterday
Gainers NanoVibronix, Inc. (NASDAQ:NAOV) shares jumped 33.7% to close at $3.37 on Monday after the company announced plan to expand product port…
Ligand Pharmaceuticals Incorporated : Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
Sparsentan treatment demonstrated a statistically significant mean reduction of proteinuria from baseline after 36 weeks, more than threefold the reduction of active comparator irbesartan… | August 16, 2021
Mid-Afternoon Market Update: Dow Turns Positive; Sesen Bio Shares Plummet
Toward the end of trading Monday, the Dow traded up 0.03% to 35,526.99 while the NASDAQ fell 0.34% to 14,771.91. The S&P also rose, gaining 0….
Mid-Day Market Update: Crude Oil Down Over 2%; Travere Therapeutics Shares Jump
Midway through trading Monday, the Dow traded down 0.36% to 35,388.46 while the NASDAQ fell 1.24% to 14,639.36. The S&P also fell, dropping 0….
Travere Therapeutics, Inc. (TVTX) CEO Dr. Eric Dube on Q2 2021 Results – Earnings Call Transcript
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q2 2021 Results Conference Call July 29, 2021 04:30 PM ET Company Participants Chris Cline – SVP, IR & Corporate Communications Dr.
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
Travere (TVTX) delivered earnings and revenue surprises of 12.33% and 8.80%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Top 5 Trades of the Eaton Vance Worldwide Health Sciences Fund
GuruFocus Article or News written by Sydnee Gatewood and the topic is about: Health care-focused fund releases 2nd-quarter portfolio
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was s…
Travere Therapeutics to Report Second Quarter 2021 Financial Results
SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2021 financial…
Earnings Preview: Travere Therapeutics (TVTX) Q2 Earnings Expected to Decline
Travere (TVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stocks That Hit 52-Week Lows On Thursday
Before 10 a.m. ET Thursday, 42 stocks made new 52-week lows.
Interesting Highlights: DiDi Global (NYSE:DIDI) was the biggest company in terms …
Hedge Funds Are Crazy About ACM Research, Inc. (ACMR)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data….
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Ju…
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 14, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on July 10, 2021, the Compensation Committee…
Hedge Funds Are Crazy About Quotient Technology Inc (QUOT)
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge…
Where Do Hedge Funds Stand On Travere Therapeutics, Inc. (TVTX)?
In this article we will analyze whether Travere Therapeutics, Inc. (NASDAQ:TVTX) is a good investment right now by following the lead of some of the best…
Is Travere Therapeutics Setting Up for a Big Move? By StockNews
Is Travere Therapeutics Setting Up for a Big Move?
Travere Therapeutics (TVTX) Investor Presentation – Slideshow (NASDAQ:TVTX)
The following slide deck was published by Travere Therapeutics, Inc.
Stocks That Hit 52-Week Highs On Friday
This morning 150 companies reached new 52-week highs.
Interesting Points: Eli Lilly (NYSE:LLY) was the largest firm by market cap to set a new …
The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Jan. 14) 10X …
The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Jan. 12) …
Travere Therapeutics' sparsentan an Orphan Drug in U.S. for rare kidney disease (NASDAQ:TVTX)
Travere Therapeutics Announces Orphan Drug Designation For Sparsentan For The Treatment Of IgA Nephropathy
SAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has
Stocks That Hit 52-Week Highs On Friday
This morning 470 companies set new 52-week highs.
Facts of Interest: Tesla (NASDAQ:TSLA) was the largest firm on a market cap basis to set a …